• br Introduction In myasthenia gravis MG autoantibodies

  2025-01-21

  

  Introduction In myasthenia gravis (MG), autoantibodies against the native AChR conformation cause loss of AChR at the neuromuscular junction and fatigable muscle weakness (Newsom-Davis et al., 1993). The AChR is a pentameric transmembrane protein, with two splice forms of the α-subunit, P3A− and

• In brief serotonin can interact with classes of receptors ar

  2025-01-21

  

  In brief, serotonin can interact with 7 classes of receptors are differentiated into 14 subtypes (Barnes and Sharp, 1999). Specifically, 5-HT1A and 5-HT2C receptors have been the most widely studied in the modulation of anxiety responses (Deakin et al., 1992; Millan, 2003). However, the studies that

• br Dual role of autophagy

  2025-01-21

  

  Dual role of autophagy in human diseases Emerging evidence suggests that autophagy serves as a double-edged sword in several human diseases, such as CNS diseases (Rubinsztein et al., 2015), arteriosclerosis (Schrijvers et al., 2011) and cancer (Ozpolat and Benbrook, 2015). Likewise, currently the

• Phagosomes acquire some hydrolases early during their

  2025-01-21

  

  Phagosomes acquire some hydrolases early during their journey from the cell surface to lysosomes. An example for such hydrolase is cathepsin H which is most concentrated in the early phagosome at a pH of approximately 6.3 (Claus et al., 1998), the pH optimum of enzyme activity (Schwartz and Barrett,

• Finally not only can ERs pair with

  2025-01-20

  

  Finally, not only can ERs pair with different mGluRs in different R788 B-cell receptor signaling regions, but it is becoming increasingly clear that the same mGluRs can pair with distinct downstream signaling partners to have differential effects both within and across brain regions (Gross et al.,

• The neural circuitry involved in

  2025-01-20

  

  The neural circuitry involved in the production of the EOD, its modulations, and in the sensory processing of communication signals has been well characterized (Bell and Maler, 2005; Chacron et al., 2011; Krahe and Maler, 2014; reviewed in Metzner, 1999). Pacemaker cells located in the pacemaker nuc

• In order to determine whether the faster Rh induced apoptosi

  2025-01-20

  

  In order to determine whether the faster Rh2-induced apoptosis is specific of cholesterol depletion, we determined the cytotoxic effect of Rh2 in Nutlin 3 depleted or not in sphingomyelin, another abundant plasma membrane lipid exhibiting enrichment in lipid rafts. We showed that, in contrast to ch

• br Results br Discussion AP

  2025-01-20

  

  Results Discussion AP-1, a heterodimeric transcription factor comprising various combinations of FOS, JUN, MAF, ATF, and CREB family proteins, has been known to play a pivotal role in leukocyte development for decades (Liebermann et al., 1998; Valledor et al., 1998). However, its participation

• br Experimental EPR spectra of probes a f were recorded

  2025-01-20

  

  Experimental EPR spectra of probes 1a–f were recorded on a Bruker EMX-1572 operating at X-band (9.0–9.9 GHz), at 21 ± 1 °C. The EPR parameters were the same in all experiments: microwave power, 1 mW; modulation amplitude, 5 G; time constant, 10.24 ms; and conversion time, 40.96 ms. Reduced gluta

• Dyphylline australia br Experimental All reagents were analy

  2025-01-20

  

  Experimental All reagents were analytical grade and were used without further purification. The morphology was characterized using a field emission scanning electron microscope (Philips XL-30 FESEMFeSEM, ZEISS SUPRA 40VP, Germany). The hydrogel sample used for SEM analysis was freeze dried. All e

• br Technical Note Fungal spoilage of dairy products

  2025-01-20

  

  Technical Note Fungal spoilage of dairy products remains a major concern for dairy manufacturers despite the use of preventive and control approaches, including the use of chemical preservatives. Among methods that are increasingly used by industries for microbial contaminant control, biopreserva

• The major phase trial NCT enrolled participants with mild to

  2025-01-20

  

  The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef

• Here we provide evidence that NO

  2025-01-20

  

  Here, we provide evidence that NO contributes to changes in synaptic strength, but also offer an explanation as to why previous attempts to link NO to LTP have often failed. Our results describe a model by which cycling AMPARs, held in intracellular pools, are rapidly delivered to the membrane surfa

• Although several ARIs have reached various phases of clinica

  2025-01-20

  

  Although several ARIs have reached various phases of clinical experimentation however most of them have been withdrawn either due to an insufficient bioavailability, their poor efficacy or adverse side effects. Currently Epalrestat is in clinical use for the treatment of diabetic neuropathy. The sid

• myc inhibitor br Discussion The clinical course of our patie

  2025-01-18

  

  Discussion The clinical course of our patient until May 2012 was rather typical of early onset AChR-MG. Later on, the pattern of the disease was more typical of MuSK-MG, as evidenced by the distribution of myasthenic weakness and the unprovoked exacerbations. The myc inhibitor of MuSK-MG appears

14391 records 23/960 page Previous Next First page 上5页 2122232425 下5页 Last page